## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.16 indicates fundamental undervaluation. Quality metrics strong (ROE 62%). Caution: momentum weakening (-3.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($110.51)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. How Leadership Changes At DaVita (DVA) Have Changed Its Investment Story**
- Source: Simply Wall Street | 20251217T130759 | Neutral | Relevance: 100%
- DaVita Inc. has recently appointed Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, signaling a focus on culture, patient care, and long-term strategy amidst operational and cost pressures. While these leadership changes are more cultural than immediately catalytic, the company's expanded credit facilities provide financial flexibility to manage elevated operating costs and cyber recovery spending. Investors should consider these developments alongside rising patient care costs and reimbursement risks, which continue to influence DaVita's investment narrative and profitability.

**2. Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?**
- Source: 富途牛牛 | 20251217T221020 | Bullish | Relevance: 100%
- DaVita Inc. (NYSE:DVA) has experienced significant price movements recently but is currently trading below its industry average based on its price-to-earnings ratio, suggesting it may be undervalued. With an expected profit growth of 23% over the next couple of years, the company shows a bright future outlook and potential for higher share valuation, making it an opportune time for investors to consider accumulating or buying the stock. However, potential investors should also assess the company's financial health and other risk factors.

**3. DaVita Inc. (NYSE:DVA) Given Average Rating of "Hold" by Brokerages**
- Source: MarketBeat | 20251217T130356 | Neutral | Relevance: 100%
- DaVita Inc. (NYSE:DVA) has received an average recommendation of "Hold" from eight brokerages, with the average twelve-month target price set at $148.00. The company recently reported earnings of $2.51 EPS, missing analyst estimates, and its stock is currently trading down by 1.7% at $118.00. Institutional investors hold a significant portion of the stock.

**4. Does Cigna Group’s Recent Gains Reflect Its Long Term Potential In 2025?**
- Source: Simply Wall Street | 20251217T012346 | Neutral | Relevance: 64%
- Cigna Group (NYSE:CI) is currently trading at what appears to be a significant discount, with a valuation score of 5/6 and a potential 74.0% undervaluation based on discounted cash flow analysis. The stock also trades at a lower Price/Earnings ratio (12.0x) compared to the broader healthcare industry (23.9x) and its peer group (31.2x), suggesting it is undervalued given its earnings growth outlook. Investors can explore "Narratives" on Simply Wall St to understand different assumptions influencing Cigna's fair value.

**5. VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge**
- Source: Markets Financial Content | 20251216T123400 | Somewhat-Bullish | Relevance: 63%
- VSee Health, Inc. (NASDAQ: VSEE) has secured a $6.0 million private placement, strengthening its financial position and supporting expansion. The company reported a 19% year-over-year revenue growth in Q3 2025, reaching $3.98 million, driven by its integrated telehealth platform and professional services. VSee Health is leveraging its AI-powered modular platform and strategic partnerships to lead the digital health transformation, serving clients like NASA and the U.S. Department of Health and Human Services.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 4 ($55.95M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $56M sold (4 transactions in 90 days).
2. High short interest (21.2%, 6.2 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 14.3% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.16 suggests fair value with growth premium. Forward P/E 9.1x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($56.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.3B |
| Beta | 0.99 |
| 52W Range | $113.97 - $179.60 |
| Short Interest | 21.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.16 |
| Forward P/E | 9.1 |
| Current P/E | 10.9 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.9% to -1.5% (-3.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >4.0% for momentum thesis). Below SMA200 (0.86x), long-term trend not supportive. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.46% (CS: 26) | Neutral |
| RSI_14 | 39.9 | Neutral |
| MACD Histogram | 0.14 | Bullish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 0.955x | Below |
| vs SMA200 | 0.857x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $116.17
- **Stop Loss:** $110.51 (4.9% risk)
- **Target:** $127.49 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 167
- **Position Value:** $19,400.39
- **Portfolio %:** 19.40%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*